Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  The Lancet

• Publication date

  2004-08-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(04)16894-3PMID 15325832
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.

  2004cited by this paper
• Selective cyclooxygenase‐2 inhibitors: similarities and differences

  2004cited by this paper
• Clinical Pharmacology of Platelet, Monocyte, and Vascular Cyclooxygenase Inhibition by Naproxen and Low-Dose Aspirin in Healthy Subjects

  2004cited by this paper
• Uninvestigated dyspepsia and non‐ulcer dyspepsia—the use of endoscopy and the roles of Helicobacter pylori eradication and antisecretory therapy

  2004cited by this paper
• Therapeutic Arthritis Research and Gastrointestinal Event Trial of lumiracoxib – study design and patient demographics

  2004cited by this paper
• Nonsteroidal anti-Inflammatory drugs and cardiovascular risk.

  2004cited by this paper
• Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects.

  2004cited by this paper
• Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.

  2004cited by this paper
• Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults

  2004cited by this paper
• Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly.

  2003cited by this paper
• Burden of major musculoskeletal conditions.

  2003cited by this paper
• Effect of ibuprofen on cardioprotective effect of aspirin.

  2003cited by this paper
• COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease☆

  2003cited by this paper
• Association between naproxen use and protection against acute myocardial infarction.

  2002cited by this paper
• COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease.

  2002cited by this paper
• The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors.

  2002cited by this paper
• Nonsteroidal anti-inflammatory drug use and acute myocardial infarction.

  2002cited by this paper
• Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.

  2002cited by this paper
• Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey.

  2002cited by this paper
• Circulating soluble E-selectin in early rheumatoid arthritis: a prospective five year study

  2002cited by this paper
• Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis.

  2002cited by this paper
• Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib

  2001cited by this paper
• Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo.

  2001cited by this paper
• Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.

  2001cited by this paper
• Cyclooxygenase-2–Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients

  2001cited by this paper
• Risk of cardiovascular events associated with selective COX-2 inhibitors.

  2001cited by this paper
• Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX‐2 versus COX‐1 in Healthy Volunteers

  2000cited by this paper
• Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

  2000cited by this paper
• Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

  2000cited by this paper
• Basic biology and clinical application of specific cyclooxygenase-2 inhibitors.

  2000cited by this paper
• Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations

  1999cited by this paper
• Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.

  1999cited by this paper
• AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology.

  1999cited by this paper
• Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology.

  1999cited by this paper
• Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

  1998cited by this paper
• Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients

  1994cited by this paper
• Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

  1994cited by this paper
• Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias.

  1990cited by this paper

• PharmGEO: A Curated Atlas of Drug-Response Transcriptomes Enabling Cross-Study Comparisons.

  2026cites this paper
• Mechanisms Involved in the Adverse Cardiovascular Effects of Selective Cyclooxygenase-2 Inhibitors

  2025cites this paper
• Cardioprotective role of royal jelly in the prevention of celecoxib-mediated cardiotoxicity in adult male albino rats

  2024cites this paper
• Modification of ibuprofen to improve the medicinal effect; structural, biological, and toxicological study

  2024cites this paper
• [Current challenges for therapy of comorbid patients: a new look at celecoxib. A review].

  2024cites this paper
• The value of correctly diagnosing axial spondyloarthritis for patients and society.

  2023cites this paper
• Student and the Lanarkshire milk experiment

  2022cites this paper
• Enhanced removal of ibuprofen in water using dynamic dialysis of laccase catalysis

  2022cites this paper
• Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.

  2020cites this paper
• Practice Advisory on the Appropriate Use of NSAIDs in Primary Care

  2020cites this paper
• Clustered allocation as a way of understanding historical controls: Components of variation and regulatory considerations

  2020cites this paper
• Hypertensive Cardiotoxicity in Cancer Treatment—Systematic Analysis of Adjunct, Conventional Chemotherapy, and Novel Therapies—Epidemiology, Incidence, and Pathophysiology

  2020cites this paper
• Risk of Intracranial Hemorrhage With Concomitant Use of Antidepressants and Nonsteroidal Anti-inflammatory Drugs: A Nested Case-Control Study

  2020cites this paper
• Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders

  2019cites this paper
• Melatonin as an armament against non-steroidal anti-inflammatory drug induced gastric injury: An overview

  2019cites this paper
• Langfassung zur S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen, Update 2019

  2019cites this paper
• Differences in cardiovascular safety with non‐steroidal anti‐inflammatory drug therapy—A nationwide study in patients with osteoarthritis

  2019cites this paper
• Pleiotropic roles of melatonin against oxidative stress mediated tissue injury in the gastrointestinal tract: An overview

  2019cites this paper
• Drug-Induced Hypertension.

  2019cites this paper
• Improving Outcomes in Prostate Cancer

  2019cites this paper
• A Novel Synthesized Sulfonamido-Based Gallate-JEZTC Blocks Cartilage Degradation on Rabbit Model of Osteoarthritis: An in Vitro and in Vivo Study

  2018cites this paper
• Intra-Articular Injection of Alginate-Microencapsulated Adipose Tissue-Derived Mesenchymal Stem Cells for the Treatment of Osteoarthritis in Rabbits

  2018cites this paper
• A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly

  2018cites this paper
• Six-month safety evaluation of robenacoxib tablets (Onsior™) in dogs after daily oral administrations

  2018cites this paper
• Safety Considerations in Prescription of NSAIDs for Musculoskeletal Pain: A Narrative Review

  2018cites this paper
• Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited

  2018influential citation
• Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain

  2018cites this paper
• Phase II study of celecoxib with docetaxel chemoradiotherapy followed by consolidation chemotherapy docetaxel plus cisplatin with maintenance celecoxib in inoperable stage III nonsmall cell lung cancer

  2018cites this paper
• Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project

  2018cites this paper
• Cyclooxygenase Inhibition: Pain, Inflammation, and the Cardiovascular System

  2017cites this paper
• Hot Topics in Primary Care: The Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drugs: Putting the Evidence in Perspective.

  2017cites this paper
• Cardiovascular Safety and Bleeding Risk Associated with Nonsteroidal Anti-Inflammatory Medications in Patients with Cardiovascular Disease

  2017cites this paper
• University of Southern Denmark Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib

  2017cites this paper
• Impact of non-steroidal anti-inflammatory drugs on cardiovascular risk: Is it the same in osteoarthritis and rheumatoid arthritis?

  2017cites this paper
• Non‐steroidal anti‐inflammatory drug‐induced cardiovascular adverse events: a meta‐analysis

  2017cites this paper
• Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease

  2017cites this paper
• Fragility Fractures Are Associated with an Increased Risk for Cardiovascular Events in Women and Men with Rheumatoid Arthritis: A Population-based Study

  2017cites this paper
• PPAR-δ Agonist With Mesenchymal Stem Cells Induces Type II Collagen-Producing Chondrocytes in Human Arthritic Synovial Fluid

  2017cites this paper
• Cardiovascular Toxicity of Cyclooxygenase Inhibitors and Promising Natur a l Substitutes.

  2017cites this paper
• Evolution of Small-Molecule Immunology Research—Changes Since CMC II

  2017cites this paper
• Can We Identify Patients at High Risk of Harm under a Generally Safe Intervention

  2017cites this paper
• Prospektive Beobachtungsstudie zur Beurteilung der Thrombozytenfunktion bei Patienten mit Karotisstenose

  2017cites this paper
• Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial

  2017cites this paper
• Effects of Non-Steroidal Anti-Inflammatory Drugs on the Gastrointestinal and Cardiovascular System

  2016cites this paper
• Balancing cardiovascular and gastrointestinal risks in patients with osteoarthritis receiving nonsteroidal anti‑inflammatory drugs. A summary of guidelines from an international expert group.

  2016cites this paper
• Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT)

  2016cites this paper
• Celecoxib for the treatment of atherosclerosis

  2016cites this paper
• Clinical Pharmacology and Cardiovascular Safety of Naproxen

  2016cites this paper
• Safety Studies for Use of Adipose Tissue‐Derived Mesenchymal Stromal/Stem Cells in a Rabbit Model for Osteoarthritis to Support a Phase I Clinical Trial

  2016cites this paper
• Rheumatologische Schmerztherapie mit nichtsteroidalen Antirheumatika

  2016cites this paper
• Aspirin, stroke and drug-drug interactions.

  2016cites this paper
• Hypertensive Crisis: The Causative Effects of Nonsteroidal Anti-Inflammatory Drugs

  2016cites this paper
• COX-2-dependent and independent effects of COX-2 inhibitors and NSAIDs on proatherogenic changes in human monocytes/macrophages

  2016cites this paper
• Randomised trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib

  2016cites this paper
• Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risks

  2016cites this paper
• Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population‐Based Cohort Study

  2015cites this paper
• Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.

  2015cites this paper
• Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs.

  2015cites this paper
• Comment utiliser les antalgiques non opiacés en postopératoire

  2015cites this paper
• Non-steroidal anti-inflammatory drugs and cardiovascular risk: At crossroads.

  2015cites this paper
• THE NON-STEROIDAL ANTI- INFLAMMATORY DRUGS-MYOCARDIAL INFARCTION ASSOCIATION: AN INVESTIGATION OF KENTUCKY MEDICAID PRESCRIPTION CLAIMS

  2015cites this paper
• Adverse Drug Reactions Attributed to Ibuprofen

  2015cites this paper
• Treatment of ankylosing spondylitis.

  2015cites this paper
• Web appendix 3

  2015cites this paper
• PharmGKB summary: ibuprofen pathways

  2015cites this paper
• [Postoperative non-opioid analgesics management].

  2015cites this paper
• Antiplatelet drug resistance: Molecular insights and clinical implications.

  2015cites this paper
• Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks

  2015cites this paper
• Therapeutic Effect of Chenodeoxycholic Acid in an Experimental Rabbit Model of Osteoarthritis

  2015cites this paper
• Decreasing cartilage damage in a rat model of osteoarthritis by intra-articular injection of deoxycholic acid.

  2015cites this paper
• The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi Arabia

  2015cites this paper
• Comparative evaluation of cardiovascular outcomes in patients with osteoarthritis and rheumatoid arthritis on recommended doses of nonsteroidal anti-inflammatory drugs

  2014cites this paper
• Differential pharmacokinetics and pharmacokinetic/pharmacodynamic modelling of robenacoxib and ketoprofen in a feline model of inflammation.

  2014cites this paper
• Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs

  2014cites this paper
• Assessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity

  2014influential citation
• DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen

  2014cites this paper
• El endotelio vascular

  2014cites this paper
• Mechanisms of aspirin resistance.

  2014cites this paper
• A cohort study to evaluate cardiovascular risk of selective and nonselective cyclooxygenase inhibitors (COX-Is) in arthritic patients attending orthopedic department of a tertiary care hospital

  2014cites this paper
• A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model

  2014cites this paper
• Cost Effectiveness of Duloxetine for Osteoarthritis: A Quebec Societal Perspective

  2014cites this paper
• Nonsteroidal Anti‐inflammatory Drugs – Cyclooxygenase‐2 Inhibitors: Risks and Benefits

  2014cites this paper
• Similar Maximum Systemic but not Local Cyclooxygenase-2 Inhibition by 50 mg Lumiracoxib and 90 mg Etoricoxib: A Randomized Controlled Trial in Healthy Subjects

  2014cites this paper
• DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen

  2014cites this paper
• Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials.

  2013cites this paper
• Ibuprofen: Pharmacology, Therapeutics and Side Effects

  2013cites this paper
• Authors are also reviewers: problems in assigning cause for missing negative studies

  2013cites this paper
• Cost-Effectiveness of Duloxetine in Chronic Low Back Pain: A Quebec Societal Perspective

  2013cites this paper
• Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective

  2013cites this paper
• The Cost-effectiveness of Celecoxib versus Non-steroidal Anti-inflammatory Drugs plus Proton-pump Inhibitors for Treating Osteoarthritis in Algeria

  2013cites this paper
• Efficacy and safety of short-term use of COX-2 inhibitors in patients after an acute stroke with musculoskeletal pain

  2013cites this paper
• Cardiovascular risk and inhibition of cyclooxygenase: traditional nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors

  2013influential citation
• Issues in performing a network meta-analysis

  2013cites this paper
• Getting to the heart of the matter: a trialist's approach to the use of nonsteroidal anti‑inflammatory drugs for patients with chronic pain syndromes.

  2013cites this paper
• Relative Cardiovascular and Gastrointestinal Safety of Non-selective Non-steroidal Anti-inflammatory Drugs Versus Cyclo-oxygenase-2 Inhibitors

  2013influential citation
• Cost-Effectiveness Analyses of Osteoarthritis Oral Therapies: a Systematic Review

  2013influential citation
• Eicosanoids and Their Drugs in Cardiovascular Diseases: Focus on Atherosclerosis and Stroke

  2013cites this paper
• Pharmacokinetics and pharmacodynamics of some NSAIDs in horses: A pharmacological, biochemical and forensic study

  2013cites this paper
• Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors.

  2013cites this paper
• The cost-effectiveness of duloxetine in chronic low back pain: a US private payer perspective.

  2013cites this paper